Glokom ve topikal antiglokom ilaçların depresyonla ilişkisi
[ X ]
Tarih
2007
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Gazi Göz Vakfı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Amaç: Bu çalışmada glokom, topikal antiglokom tedavisi ve depresyon arasındaki ilişki araştırıldı. Gereç ve Yöntem: Çalışmaya glokomlu olan ve topikal antig- lokom ilaç tedavisi alan 120 olgu dahil edildi. Olguların yaş ortalaması 52.37±16.46 yıl olup, 64’ü erkek, 56’sı kadındı. Antiglokom tedavisi alan hasta grubu, topikal beta bloker kullananlar ve topikal prostaglandin analo- gu kullananlar olmak üzere iki gruba ayrılarak değerlen- dirildi. Kontrol grubu olarak kırılma kusuru dışında göz ve sistemik rahatsızlığı olmayan aynı yaş grubu 60 olgu dahil edildi. Kontrol grubundaki olguların yaş ortalaması 51.80±13.96 yıl olup 36’sı erkek, 24’ü kadındı. Çalışma- ya alınan bireylere demografik veri formu, depresyon ta- nısı için yapılandırılmış klinik görüşme çizelgesi klinik ver- siyonu (SCID I) ve depresyon şiddeti için Beck depresyon envanteri (BDE) uygulandı. Bulgular: Glokomlu olgu grubunda depresyon oranı (%25.2) kontrol gurubuna (%10) göre daha yüksekti (p=0.013). Beta bloker kullananlarda depresyon oranı %29.50, pros- taglandin analogu kullananlarda ise %22.03 idi ve arala- rında istatiksel olarak anlamlı fark yoktu (p=0.350). Ancak beta bloker kullananlarda BDE puanlarına göre depresyon şiddeti, prostaglandin analogu kullanan olgular (p=0.010) ve kontrol grubundan (p=0.000) daha yüksekti. Sonuç: Glokomlu hasta grubunda depresyon oranı kontrol grubuna göre daha yüksekti. Ayrıca tedavi olarak topi- kal beta bloker kullananlarda ortalama depresyon pua- nı, prostaglandin analogu kullananlara göre daha yüksek bulundu. Glokom tedavisi için başvuranlarda ve tedavide beta bloker kullananlarda bu durumun göz önünde bulun- durulması gerektiğini düşünüyoruz.
Purpose: Ta investigate, the relationship between depression and glaucoma and topical antiglaucoma treatment. Materials and Methods: A total of 120 patients with glauco- ma who were treated with topical antiglaucoma agents were included in the study. Mean age of the patients was 52.37±16.46 years: 64 patients were male and 56 were female. The patients receiving antiglaucomatous treatment were evaluated in two separate groups: those who used topical beta blockers and those who used topical prostag- landin analogues. In addition, 60 subjects of the same age group, who had no systemic or ophthalmologic diseases except for refractive errors, were included in the study as controls. Mean age of those subjects in the control gro- up was 51.80±13.96: 36 of controls were male and 24 female. All subjects included in the study were evaluated through, sociodemographic data form, Structural Clinical Interview for DSM-IV (SCID) for diagnosis of depression, and Beck Depression Inventory (BDI) for the severity of depression. Results: The depression rate in the glaucoma group (25.2%) was higher than that in the control group (10%) (p=0.013). The depression rate was 29.5% in patients who used beta blockers and 22.03% in those using prostaglandin analo- gues, and statistically there was no significant difference between them (p=0.350). However, the severity of dep- ression according to BDI score was higher in patients who used beta blockers than those in the other group who used prostaglandin analogues (p=0.010), as well as the cont- rols (p=0.000). Conclusion: The depression rate was higher in patients with glaucoma with respect to the controls. Also, the average depression score was found to be higher in patients who used topical beta blockers as treatment in than those who used prostaglandin analogues. We are of the opinion that this situation should be taken into consideration in patients with glaucoma and in those using beta blockers.
Purpose: Ta investigate, the relationship between depression and glaucoma and topical antiglaucoma treatment. Materials and Methods: A total of 120 patients with glauco- ma who were treated with topical antiglaucoma agents were included in the study. Mean age of the patients was 52.37±16.46 years: 64 patients were male and 56 were female. The patients receiving antiglaucomatous treatment were evaluated in two separate groups: those who used topical beta blockers and those who used topical prostag- landin analogues. In addition, 60 subjects of the same age group, who had no systemic or ophthalmologic diseases except for refractive errors, were included in the study as controls. Mean age of those subjects in the control gro- up was 51.80±13.96: 36 of controls were male and 24 female. All subjects included in the study were evaluated through, sociodemographic data form, Structural Clinical Interview for DSM-IV (SCID) for diagnosis of depression, and Beck Depression Inventory (BDI) for the severity of depression. Results: The depression rate in the glaucoma group (25.2%) was higher than that in the control group (10%) (p=0.013). The depression rate was 29.5% in patients who used beta blockers and 22.03% in those using prostaglandin analo- gues, and statistically there was no significant difference between them (p=0.350). However, the severity of dep- ression according to BDI score was higher in patients who used beta blockers than those in the other group who used prostaglandin analogues (p=0.010), as well as the cont- rols (p=0.000). Conclusion: The depression rate was higher in patients with glaucoma with respect to the controls. Also, the average depression score was found to be higher in patients who used topical beta blockers as treatment in than those who used prostaglandin analogues. We are of the opinion that this situation should be taken into consideration in patients with glaucoma and in those using beta blockers.
Açıklama
Anahtar Kelimeler
Beta bloker, Depresyon, Glokom, Prostaglandin analogu, Beta blocker, Depression, Glaucoma, Prostaglandin analogue
Kaynak
Glokom Katarakt
WoS Q Değeri
Scopus Q Değeri
Cilt
2
Sayı
4
Künye
Keklikçi, U., Yaşan, A., Ünlü, K., Ceylan, V. ve Balsak, S. (2007). Glokom ve topikal antiglokom ilaçların depresyonla ilişkisi. Glokom Katarakt, 2(4), 255-259.
